About Leap Therapeutics (NASDAQ:LPTX)
Leap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-2.13
Forward P/E Ratio-2.98
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book7.84
EPS (Most Recent Fiscal Year)($3.31)
Return on Equity-182.37%
Return on Assets-121.19%
Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions
What is Leap Therapeutics' stock symbol?
Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
How were Leap Therapeutics' earnings last quarter?
Leap Therapeutics (NASDAQ:LPTX) released its quarterly earnings results on Friday, February, 23rd. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.12. View Leap Therapeutics' Earnings History.
What price target have analysts set for LPTX?
1 analysts have issued 1-year price targets for Leap Therapeutics' stock. Their forecasts range from $12.50 to $12.50. On average, they anticipate Leap Therapeutics' share price to reach $12.50 in the next year. View Analyst Ratings for Leap Therapeutics.
What are Wall Street analysts saying about Leap Therapeutics stock?
Here are some recent quotes from research analysts about Leap Therapeutics stock:
- 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)
- 2. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (1/23/2018)
Who are some of Leap Therapeutics' key competitors?
Some companies that are related to Leap Therapeutics include Syros Pharmaceuticals (SYRS), Cytokinetics (CYTK), Kala Pharmaceuticals (KALA), GTX (GTXI), Albireo (ALBO), Clearside Biomedical (CLSD), Dermira (DERM), Corbus Pharmaceuticals (CRBP), Unum Therapeutics (UMRX), Corium International (CORI), Mersana Therapeutics (MRSN), Strongbridge Biopharma (SBBP), Merus (MRUS), Paratek Pharmaceuticals (PRTK) and Kadmon (KDMN).
Has Leap Therapeutics been receiving favorable news coverage?
Press coverage about LPTX stock has trended somewhat positive on Thursday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Leap Therapeutics earned a coverage optimism score of 0.11 on Accern's scale. They also gave press coverage about the company an impact score of 47.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Leap Therapeutics?
Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Leap Therapeutics' stock price today?
One share of LPTX stock can currently be purchased for approximately $7.06.
How big of a company is Leap Therapeutics?
Leap Therapeutics has a market capitalization of $98.89 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.
How can I contact Leap Therapeutics?
Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.
MarketBeat Community Rating for Leap Therapeutics (LPTX)MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Leap Therapeutics (NASDAQ:LPTX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Leap Therapeutics (NASDAQ LPTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 58.70%
Institutional Ownership Percentage: 2.77%
Leap Therapeutics (NASDAQ LPTX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/14/2017||Augustine Lawlor||COO||Buy||1,057,769||$6.09||$6,441,813.21|| |
Leap Therapeutics (NASDAQ LPTX) News Headlines
Leap Therapeutics (NASDAQ:LPTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Leap Therapeutics (NASDAQ:LPTX) Income Statement, Balance Sheet and Cash Flow Statement
Leap Therapeutics (NASDAQ LPTX) Stock Chart for Thursday, April, 26, 2018